There has been an increasing standard of living in the Middle East and Africa due to higher national income. This has contributed to a higher incidence of heart disease - high blood pressure, high cholesterol and high blood sugar. In fact, the Middle East/Africa region is one of the higher areas for heart disease which has prompted more individuals being admitted to the hospital. This has caused an uptick in the demand for diagnostic testing devices and medical devices.
This report provides an overview of developments in the in vitro diagnostics industry in the Middle East and Africa. The countries covered are
- Egypt
- Iran
- Iraq
- Israel
- Jordan
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates (UAE)
- Other Mideast (Bahrain, Cyprus, Gaza Strip, Kuwait, Lebanon, Oman, Qatar, Syria, West Bank, Yemen)
- Other Africa (Algeria, Congo, Sudan, Libya, Chad, Niger, Angola, Mali, Ethiopia, etc.)
Scope
The Middle East, Africa market for in vitro diagnostics is provided in U.S. dollars for the years 2021 - 2026.
The report covers six segments of the IVD market in the Middle East:
- Clinical Chemistry
- Immunoassay
- Microbiology
- Point of Care (POC)
- Histology - traditional stains
- Other (includes nucleic acid assays, blood bank ABO, sequencing, prenatal tests and other areas not covered specifically in the above segments)
Table of Contents
Companies Mentioned
- 10x Genomics
- Bio-Rad
- Dolomite Bio
- Fluidigm
- Illumina
- Mission Bio
- Qiagen
- Takara Bio
